Journal article
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
- Abstract:
-
Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation block. Single-agent enasidenib (AG-221/CC-90007), a selective mutant IDH2 (mIDH2) inhibitor, produced an overall response rate of 40.3% in relapsed/refractory AML (rrAML) patients with mIDH2 in a ph...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted manuscript
Actions
Access Document
- Files:
-
-
(pdf, 173.4KB)
-
- Publisher copy:
- 10.1182/blood-2017-04-779447
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
Bibliographic Details
- Publisher:
- American Society of Hematology Publisher's website
- Journal:
- Blood Journal website
- Volume:
- 130
- Issue:
- 6
- Pages:
- 732-741
- Publication date:
- 2017-08-10
- Acceptance date:
- 2017-05-28
- DOI:
- EISSN:
-
1528-0020
- ISSN:
-
0006-4971
- Pubs id:
-
pubs:700685
- URN:
-
uri:fe1cab64-86fd-40ed-9bbe-700d65bd7794
- UUID:
-
uuid:fe1cab64-86fd-40ed-9bbe-700d65bd7794
- Local pid:
- pubs:700685
Item Description
- Language:
- English
Terms of use
- Copyright holder:
- American Society of Hematology
- Copyright date:
- 2017
- Notes:
- © 2017 by The American Society of Hematology. This is the author accepted manuscript following peer review version of the article. The final version is available online from American Society of Hematology at: 10.1182/blood-2017-04-779447
If you are the owner of this record, you can report an update to it here: Report update to this record